Skip to main content
Premium Trial:

Request an Annual Quote

For the Risk Takers

The US National Institutes of Health has granted 81 awards under its High Risk-High Reward program, the agency says. "The Common Fund High Risk-High Reward program provides opportunities for innovative investigators in any area of health research to take risks when the potential impact in biomedical and behavioral science is high," says NIH Director Francis Collins in a statement.

Among this winners of this year's NIH Director's Pioneer award, which is open to investigators at all career stages, are Edward Marcotte from the University of Texas, Austin, Stanford University's Christina Smolke, and Feng Zhang of the Broad Institute.

This year's New Innovator awards went to 51 researchers including the University of Washington's Elhanan Borenstein, Andrew Goodman at Yale University, Mount Sinai School of Medicine's Anne Schaefer, and Pennsylvania State University's Siyang Zheng, among others.

Finally, the recipients of the NIH Director's Transformative Research Projects awards, which promote interdisciplinary research, include the Broad's David Altshuler, Harvard's Chad Cowan, Thomas Tuschl at Rockefeller University, Uwe Ohler at Duke University, and Sloan-Kettering Institute for Cancer Research's Dinshaw Patel.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.